-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Baili Tianheng (688506.SH) announced that the innovative biopharmaceutical T-Bren (HER2 ADC) independently developed by the company has recently completed the first phase III randomized controlled clinical trial comparing T-Bren with doctor-selected chemotherapy in patients with locally advanced or metastatic biliary tract cancer with HER2 expression who failed to be treated with platinum-containing chemotherapy.

Zhitongcaijing·07/26/2026 07:57:01
Listen to the news
Zhitong Finance App News, Baili Tianheng (688506.SH) announced that the innovative biopharmaceutical T-Bren (HER2 ADC) independently developed by the company has recently completed the first phase III randomized controlled clinical trial comparing T-Bren with doctor-selected chemotherapy in patients with locally advanced or metastatic biliary tract cancer with HER2 expression who failed to be treated with platinum-containing chemotherapy.